Reduced expansion of CD94/NKG2C
Adult
Aged
Aged, 80 and over
B-Lymphocytes
/ pathology
Cohort Studies
Cytomegalovirus
/ isolation & purification
Cytomegalovirus Infections
/ complications
Female
Gene Deletion
Humans
Killer Cells, Natural
/ pathology
Leukemia, Lymphocytic, Chronic, B-Cell
/ complications
Lymphocytosis
/ complications
Male
Middle Aged
NK Cell Lectin-Like Receptor Subfamily C
/ analysis
NK Cell Lectin-Like Receptor Subfamily D
/ analysis
HLA-E
NKG2C
chronic lymphocytic leukemia
human cytomegalovirus
monoclonal B cell lymphocytosis
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
29
01
2021
received:
20
11
2020
accepted:
06
02
2021
pubmed:
23
2
2021
medline:
30
11
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Dysregulated NK cell-mediated immune responses contribute to tumor evasion in chronic lymphocytic leukemia (CLL), although the NK cell compartment in CLL-like monoclonal B-cell lymphocytosis (MBL) is poorly understood. In healthy individuals, human cytomegalovirus (HCMV) induces the expansion of NK cells expressing high levels of CD94/NKG2C NK cell receptor (NKR) specific for HLA-E. We analyzed the expression of NKG2A, NKG2C, ILT2, KIR, CD161, and CD57 in 24 MBL and 37 CLL. NKG2C was genotyped in these patients and in 81 additional MBL/CLL, while NKG2C gene expression was assessed in 26 cases. In 8 CLL patients with increased lymphocytosis (≥20 × 10 NKR distribution did not significantly differ between MBL and CLL patients, although they exhibited reduced NKG2C Reduced percentages of CD94/NKG2C
Substances chimiques
KLRC2 protein, human
0
KLRD1 protein, human
0
NK Cell Lectin-Like Receptor Subfamily C
0
NK Cell Lectin-Like Receptor Subfamily D
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032-1040Subventions
Organisme : Fundació La Caixa
Organisme : Fundación Española de Hematología y Hemoterapia (FEHH-Janssen)
Organisme : Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
ID : 2014/SGR585
Organisme : Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
ID : 2017/SGR437
Organisme : Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness
ID : PI11/1621
Organisme : Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness
ID : PI15/437
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412-1421. https://doi.org/10.1182/blood-2012-02-411678
Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797-1805. https://doi.org/10.1172/JCI24176
Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-1621. https://doi.org/10.1182/blood-2012-09-457531
Veuillen C, Aurran-Schleinitz T, Castellano R, et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol. 2012;32(3):632-646. https://doi.org/10.1007/s10875-011-9624-5
Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, et al. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One. 2014;9(10):e108326. https://doi.org/10.1371/journal.pone.0108326
Parry HM, Stevens T, Oldreive C, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget. 2016;7(42):68513-68526. https://doi.org/10.18632/oncotarget.12097
MacFarlane AW, Jillab M, Smith MR, et al. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology. 2017;6(7):e1330235. https://doi.org/10.1080/2162402X.2017.1330235
Hofland T, Endstra S, Gomes CKP, et al. Natural Killer cell hypo-responsiveness in chronic lymphocytic leukemia can be circumvented in vitro by adequate activating signaling. Hemasphere. 2019;3(6):e308. https://doi.org/10.1097/HS9.0000000000000308
Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575-583. https://doi.org/10.1056/NEJMoa075290
Vardi A, Dagklis A, Scarfò L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 2013;121(22):4521-4528. https://doi.org/10.1182/blood-2012-12-471698
Blanco G, Puiggros A, Sherry B, et al. Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. Exp Hematol. 2021;1:1-13. https://doi.org/10.1016/j.exphem.2020.12.007
D'Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in “clinical” monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol. 2011;24(4):915-923. https://doi.org/10.1177/039463201102400410
Rissiek A, Schulze C, Bacher U, et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia. Int J Cancer. 2014;135(10):2370-2379. https://doi.org/10.1002/ijc.28884
Blanco G, Vardi A, Puiggros A, et al. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. Oncoimmunology. 2018;7(6):e1432328. https://doi.org/10.1080/2162402X.2018.1432328
te Raa GD, Tonino SH, Remmerswaal EB, et al. Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. LeukLymphoma. 2012;53(11):2321-2325. https://doi.org/10.3109/10428194.2012.698277
Pourgheysari B, Bruton R, Parry H, et al. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B cell chronic lymphocytic leukemia and determines the total CD4+ T cell repertoire. Blood. 2010;116(16):2968-2974. https://doi.org/10.1182/blood-2009-12-257147
te Raa GD, Pascutti MF, García-Vallejo JJ, et al. CMV-specific CD8+ T cell function is not impaired in chronic lymphocytic leukemia. Blood. 2014;123(5):717-724. https://doi.org/10.1182/blood-2013-08-518183
Gumá M, Angulo A, Vilches C, et al. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 2004;104(12):3664-3671. https://doi.org/10.1182/blood-2004-05-2058
López-Botet M, Muntasell A, Vilches C. The CD94/NKG2C+ NK cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. Semin Immunol. 2014;26(2):145-151. https://doi.org/10.1016/j.smim.2014.03.002
Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391(6669):795-799. https://doi.org/10.1038/35869
Tomasec P, Braud VM, Rickards C, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science. 2000;287(5455):1031. https://doi.org/10.1126/science.287.5455.1031
Hammer Q, Rückert T, Borst EM, et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat Immunol. 2018;19(5):453-463. https://doi.org/10.1038/s41590-018-0082-6
Muntasell A, López-Montañés M, Vera A, et al. NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol. 2013;43(12):3268-3278. https://doi.org/10.1002/eji.201343773
Muntasell A, Vilches C, Angulo A, López-Botet M. Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction. Eur J Immunol. 2013;43(5):1133-1141. https://doi.org/10.1002/eji.201243117
Goodier MR, White MJ, Darboe A, et al. Rapid NK cell differentiation in a population with near-universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood. 2014;124(14):2213-2222. https://doi.org/10.1182/blood-2014-05-576124
Ataya M, Redondo-Pachón D, Llinàs-Mallol L, et al. Pretransplant adaptive NKG2C+ NK cells protect against cytomegalovirus infection in kidney transplant recipients. Am J Transplant. 2020;20(3):663-676. https://doi.org/10.1111/ajt.15658
Petersen L, Roug AS, Skovbo A, Thysen AH, Eskelund CW, Hokland ME. TheCD94/NKG2C-expressing NK cell subset is augmented in chronic lymphocytic leukemia patients with positive human cytomegalovirus serostatus. Viral Immunol. 2009;22(5):333-337. https://doi.org/10.1089/vim.2009.0032
Sanchez-Correa B, Morgado S, Gayoso I, et al. Human NK cells in acute myeloidleukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother. 2011;60(8):1195-1205. https://doi.org/10.1007/s00262-011-1050-2
Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C. Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction. Tissue Antigens. 2012;80(2):184-187. https://doi.org/10.1111/j.1399-0039.2012.01911.x
Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology. 2009;14(2):101-105. https://doi.org/10.1179/102453309X385197
Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sébahoun G. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology. 2012;135(2):151-157. https://doi.org/10.1111/j.1365-2567.2011.03521.x
Muntasell A, Pupuleku A, Cisneros E, et al. Relationship of NKG2C copy number with the distribution of distinct cytomegalovirus-induced adaptive NK cell subsets. J Immunol. 2016;196(9):3818-3827. https://doi.org/10.4049/jimmunol.1502438
Campos C, Pera A, Sanchez-Correa B, et al. Effect of age and CMV on NK cell subpopulations. Exp Gerontol. 2014;54:130-137. https://doi.org/10.1016/j.exger.2014.01.008
Nückel H, Rebmann V, Dürig J, Dührsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005;105(4):1694-1698. https://doi.org/10.1182/blood-2004-08-3335
Rezvany MR, Kazemi A, Hajifathali A, Kaviani S, Mellstedt H. Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. Iran Biomed J. 2007;11(2):125-129.
Giannopoulos K, Dmoszyńska A, Bojarska-Junak A, Schmitt M, Roliński J. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia Histochem Cytobiol. 2008;46(4):457-460. https://doi.org/10.2478/v10042-008-0072-x
Rizzo R, Audrito V, Vacca P, et al. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica. 2014;99(5):888-896. https://doi.org/10.3324/haematol.2013.095281
Llano M, Lee N, Navarro F, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol. 1998;28(9):2854-2863. https://doi.org/10.1002/(SICI)1521-4141(199809)28:09<2854:AID-IMMU2854>3.0.CO;2-W
Valés-Gómez M, Reyburn HT, Erskine RA, López-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999;18(15):4250-4260. https://doi.org/10.1093/emboj/18.15.4250
Lauterbach N, Wieten L, Popeijus HE, Voorter CE, Tilanus MG. HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire. Hum Immunol. 2015;76(8):578-586. https://doi.org/10.1016/j.humimm.2015.09.003